Estimation of Therapeutic Effect of MDcure on Patients With Chronic Lower Back Pain
Unknown statusPhase 4NCT02971592
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study will assess the therapeutic effect of MDcure® device. MDcure® is an FDA Class 1 listed medical device, produced to ISO-13485 standards, that delivers extremely low intensity (nano Tesla; 10-9) and low frequencies (1-100 Hertz) electromagnetic fields (EMF) intended to reduce muscular aches and pains particularly of the lower back. assessing the reduction of lower back pain. Half of participants will receive the MDcure device, while the other half will receive a mock device.
Study details
- Official title
- Estimation of Therapeutic Effect of MDcure on Patients With Chronic Back Pain
- Conditions
- Interventions
- Device: MDcure
- Other: Mock Device
- Sponsor
- Assuta Medical Center
- Collaborators
- Aerotel Ltd
- Start date
- 2017-01
- Primary completion
- 2018-11
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- Israel
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Men and women aged 18-75 * Patients with chronic lower back for more then 3 month * Patients who scored over 21% and below 60% in the Oswestry questionnaire Exclusion Criteria: * A neurological deficient in lower limbs * Patients who scored more than 60% on the Oswestry questionnaire. * Patients who underwent surgical intervention in spine including metal implant in lower back * Patients diagnosed with cancer * Patients with any type of vertebral fracture * Patients who received steroid injection less then a month prior to starting the experiment * Patients treated with steroids as a preventive treatment on a regular basis * Patients using narcotic drugs for over a six month period or cannabis or any other sort of narcotic drug for over a six month period prior to their enrollment in the study * Pregnant women
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02971592